Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
98 hedge funds and large institutions have $867M invested in Dicerna Pharmaceuticals, Inc. in 2019 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 36 increasing their positions, 24 reducing their positions, and 24 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 24
39% more capital invested
Capital invested by funds: $622M → $867M (+$245M)
0% more call options, than puts
Call options by funds: $1K | Put options by funds: $1K
5% less funds holding
Funds holding: 103 → 98 (-5)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
21% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$19.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$15.5M |
| 3 |
AG
Artal Group
Luxembourg
|
+$5.22M |
| 4 |
JP Morgan Chase
New York
|
+$4.96M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$37.2M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$13.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.51M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.88M |
| 5 |
EU
Emory University
Atlanta,
Georgia
|
-$1.84M |
DRNA Hedge Fund Activity: Q1 2019 in Review
98 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q1 2019, worth a combined $867M — up 39% from $622M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of DRNA and 19 opened new positions — a net loss of 5 holders — while 24 trimmed existing stakes and 36 added.
The largest buyer was UBS Group, adding an estimated $19.3M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $37.2M sold.
- 98 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q1 2019, down from 103 in Q4 2018.
- Funds reported $867M of Dicerna Pharmaceuticals, Inc. stock for Q1 2019, up 39% quarter-over-quarter.
- 19 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q1 2019 and 24 closed out, a net change of -5 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q1 2019 was UBS Group, an estimated $19.3M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q1 2019 was Cormorant Asset Management, an estimated $37.2M sold.
Based on aggregated 13F filings for Q1 2019.